Biotech Values

[iwfal]

OCUL Glaucoma

FWIW - both glaucoma inserts on the market, the second having just been approved, have a label restriction disallowing use more than once in an eye. For at least Durysta this was not the original plan; it just showed up in the later/bigger trials that repeated use showed problems. My point is that this was not obvious in the earlier/smaller trials that are more like this OCUL one, and I haven’t yet seen strong data on what small trial, single use proxies accurately predict that reuse risk in the later ph3.